Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06244212 · ClinicalTrials.gov registry record · NA
Topical Treatment for Atopic Dermatitis
A NA study of Atopic Dermatitis, sponsored by Wake Forest University Health Sciences.
- Recruiting
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT06244212: Recruiting NA study of Atopic Dermatitis, sponsored by Wake Forest University Health Sciences.
NCT06244212 is a NA study of Atopic Dermatitis that is actively recruiting participants, run by Wake Forest University Health Sciences. The registered enrollment target is 30 participants, below the 609-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06244212, a NA study of Atopic Dermatitis, is actively recruiting participants, sponsored by Wake Forest University Health Sciences.
- RECRUITING
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
Medication adherence is a poorly studied phenomenon that challenges both patients and physicians. 50% of individuals with chronic disease are not adherent to their medication regimen. Within the United States, non-adherence to medical treatment leads to approximately $100 billion in hospital admission costs. While the issue of adherence is not limited to any particular field of medicine, non-adherence occurs in approximately one-third to one-half of dermatological patients. Non-adherence is of importance as it is a significant cause of treatment failure, resulting in worse quality of life, worse health outcomes, and increased insurance costs.
Primary Outcome
Amount of Topical Medication Dispensed in grams
Conditions Studied
Interventions
- OTHER Standard of Care
- OTHER Demonstration of applying triamcinolone cream
- BEHAVIORAL Mobile App Use
Study Locations (1)
North Carolina
- Wake Forest University Health Sciences - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2024-09-19 |
| Est. Completion | 2027-07 |
| Phase | NA |
What NCT06244212 shows while recruiting
NCT06244212 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 609-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Atopic Dermatitis appearing as the primary indexed condition, and to 3 interventions - of which Standard of Care is the first listed.
NCT06244212 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT06244212 about?
NCT06244212 is a clinical study titled "Topical Treatment for Atopic Dermatitis". Medication adherence is a poorly studied phenomenon that challenges both patients and physicians. 50% of individuals with chronic disease are not adherent to their medication regimen. Within the United States, non-adherence to medical treatment leads to approximately $100 billion in hospital admissi...
What is the current status of trial NCT06244212?
This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2024-09-19. Estimated completion is 2027-07.
What conditions does trial NCT06244212 study?
This clinical trial studies the following conditions: Atopic Dermatitis.
What interventions are being tested in trial NCT06244212?
The interventions under investigation include: Standard of Care (OTHER), Demonstration of applying triamcinolone cream (OTHER), Mobile App Use (BEHAVIORAL).
Who is sponsoring clinical trial NCT06244212?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06244212 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atopic Dermatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06244212's enrollment target sits among peer trials
30 120th of 150 higher than 25 of 150 other Atopic Dermatitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Atopic Dermatitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Michigan Food and Atopic Dermatitis (M-FAD) Program - Molecular Analytics Project
RECRUITING · NA
-
Team-Based Connected Health (TCH) to Improve Clinical Outcomes and Access in Atopic Dermatitis
COMPLETED · NA
-
A Study Comparing the Efficacy of Two Topical Steroid Application Regimens in Pediatric Patients With Atopic Dermatitis
COMPLETED · NA
-
Asthma and Atopic Dermatitis Validation of PROMIS Pediatric Instruments
COMPLETED · NA
-
Reversal of Epidermal Phenotype in Severe Atopic Dermatitis With Cyclosporine Therapy
COMPLETED · NA
-
Comparison of Video-Based Versus Written Patient Education on Atopic Dermatitis
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI